State Street
AQST icon

State Street’s Aquestive Therapeutics AQST Stock Holding History

State Street’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
2,928,020
+381,829
+15% +$1.61M ﹤0.01% 2617
2026
Q1 		$10.6M Buy
2,546,191
+83,413
+3% +$339K ﹤0.01% 2584
2025
Q4 		$15.9M Buy
2,462,778
+860,562
+54% +$5.36M ﹤0.01% 2383
2025
Q3 		$8.96M Buy
1,602,216
+94,918
+6% +$410K ﹤0.01% 2698
2025
Q2 		$4.99M Sell
1,507,298
-15,357
-1% -$44.1K ﹤0.01% 2943
2025
Q1 		$4.42M Buy
1,522,655
+18,764
+1% +$56.8K ﹤0.01% 2934
2024
Q4 		$5.35M Buy
1,503,891
+7,152
+0.5% +$33K ﹤0.01% 2938
2024
Q3 		$7.45M Buy
1,496,739
+512,682
+52% +$2M ﹤0.01% 2769
2024
Q2 		$2.56M Buy
984,057
+802,420
+442% +$2.68M ﹤0.01% 3218
2024
Q1 		$774K Buy
181,637
+30,100
+20% +$100K ﹤0.01% 3533
2023
Q4 		$306K Buy
151,537
+14,200
+10% +$25.1K ﹤0.01% 3774
2023
Q3 		$210K Hold
137,337
– – ﹤0.01% 3927
2023
Q2 		$227K Buy
137,337
+41,300
+43% +$74.7K ﹤0.01% 3964
2023
Q1 		$109K Hold
96,037
– – ﹤0.01% 4299
2022
Q4 		$86.6K Hold
96,037
– – ﹤0.01% 4413
2022
Q3 		$112K Hold
96,037
– – ﹤0.01% 4426
2022
Q2 		$61K Hold
96,037
– – ﹤0.01% 4682
2022
Q1 		$251K Buy
96,037
+8,960
+10% +$26.2K ﹤0.01% 4305
2021
Q4 		$339K Buy
87,077
+17,200
+25% +$86.3K ﹤0.01% 4146
2021
Q3 		$305K Hold
69,877
– – ﹤0.01% 4190
2021
Q2 		$277K Sell
69,877
-253,766
-78% -$1.01M ﹤0.01% 4090
2021
Q1 		$1.68M Buy
323,643
+8,752
+3% +$46.6K ﹤0.01% 3502
2020
Q4 		$1.69M Buy
314,891
+25,047
+9% +$150K ﹤0.01% 3425
2020
Q3 		$1.41M Buy
289,844
+1,114
+0.4% +$7.28K ﹤0.01% 3335
2020
Q2 		$1.4M Buy
+288,730
New +$1.33M ﹤0.01% 3310
2019
Q2 		– Sell
-48,935
Closed -$338K – 3815
2019
Q1 		$338K Buy
48,935
+6,355
+15% +$44.5K ﹤0.01% 3504
2018
Q4 		$268K Buy
42,580
+27,780
+188% +$351K ﹤0.01% 3531
2018
Q3 		$260K Buy
+14,800
New +$244K ﹤0.01% 3564

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

State Street's AQST Position: Q2 2026 in Review

State Street increased its Aquestive Therapeutics (AQST) stake by 15% in Q2 2026, buying an estimated $1.61M and bringing the position to 2,928,020 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

State Street first reported a position in AQST in Q3 2018 and has held it in 28 quarters since. The position peaked at $15.9M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • State Street held 2,928,020 shares of Aquestive Therapeutics worth $12.2M as of Q2 2026.
  • State Street bought 381,829 Aquestive Therapeutics shares in Q2 2026, an estimated $1.61M.
  • Aquestive Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2617 holding.
  • State Street first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • State Street's Aquestive Therapeutics position peaked at $15.9M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.